Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Surgical Endoscopy|August 15, 2019
Impact of needle-based confocal laser endomicroscopy on the therapeutic management of single pancreatic cystic lesionsMaxime Palazzo, Alain Sauvanet, Rodica Gincul, et al.
European Journal of Gastroenterology & Hepatology|July 16, 2010
Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patientsRéginald Brenard, Xavier Chapaux, Pierre Deltenre, et al.
Future Oncology (London, England)|June 26, 2020
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, et al.
Journal of Neuroendocrinology|March 2, 2022
ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumorsIvan Borbath, Ulrich-Frank Pape, Pierre H Deprez, et al.
Endoscopy|February 18, 2022
Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) GuidelinePierre H Deprez, Leon M G Moons, Dermot OʼToole, et al.
BMC Cancer|April 17, 2013
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric studyAlain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, et al.
BMJ Open|July 4, 2025
Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocolSiddharth Chhajlani, Jelka Kuiper, Philippe Beutels, et al.
Oncotarget|January 26, 2017
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinomaNicola Personeni, Laura Giordano, Giovanni Abbadessa, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD studyCôme Lepage, Jean-Marc Phelip, Astrid Lievre, et al.
Oncotarget|September 1, 2016
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinibLorenza Rimassa, Giovanni Abbadessa, Nicola Personeni, et al.
Pageof 8